Plasma homocysteine and L-DOPA metabolism in patients with Parkinson disease

Clinical Chemistry

Volumn 47, Issue 6 I, 2001, Pages 1102-1104

  Blandini, F ^a   Fancellu, R ^a   Martignoni, E ^a   Mangiagalli, A ^a   Pacchetti, C ^a   Samuele, A ^a   Nappi, G ^a  

^a C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HOMOCYSTEINE; LEVODOPA;

ADULT; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG METABOLISM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOMOCYSTINURIA; HUMAN; MALE; METHYLATION; OXIDATIVE STRESS; PARKINSON DISEASE;

EID: 0035017801     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/47.6.1102     Document Type: Article

References (28)

1. Functional methionine synthase deficiency (cbIE and cbIG): Clinical and biochemical heterogeneity
2. Hyperhomocysteinaemia: With reference to its neuroradiological aspects
3. Homocysteine as a risk factor for atherosclerosis
4. Homocysteine and risk of cardiovascular disease
5. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men
6. Homocysteine mediated endothelial cell toxicity and its amelioration
7. S-adenosylmethionine levels in psychiatric and neurological disorders
8. Decreased methionine adenosyltransferase activity in erythrocytes of patients with dementia disorders
9. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity
10. The effects of L-Dopa on the activity of methionine adenosyltransferase: Relevance to L-Dopa therapy and tolerance
11. Homocyst(e)ine and coronary artery disease: Clinical evidence and genetic and metabolic background
12. Effect of L-Dopa and the catechol-O-methyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats
13. Effects of L-DOPA treatment on methylation in mouse brain: Implications for the side effects of L-DOPA
14. Sulfate and cysteine levels in the plasma of patients with Parkinson's disease
15. Elevated plasma levels of homocysteine in Parkinson's disease
16. Hyperhomocysteinaemia in Parkinson's disease
17. Nigral endothelial dysfunction, homocysteine and Parkinson's disease
18. Assessment of Parkinson's disease
19. Simultaneous determination of L-Dopa and 3-O-methyldopa in human platelets and plasma using high-performance liquid chromatography with electrochemical detection
20. A rapid and simple method for determining catecholamines in human plasma and cerebrospinal fluid using high-performance liquid chromatography with electrochemical detection
21. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD
22. Oxidative stress and the pathogenesis of Parkinson's disease
23. L-DOPA increases nigral production of hydroxyl radicals in vivo: Potential L-DOPA toxicity?
24. Toxic effects of L-DOPA on mesencephalic cell cultures: Protection with antioxidants
25. L-DOPA cytotoxicity to PC12 cells in culture is via auto-oxidation
26. Peripheral markers of oxidative stress in Parkinson's disease. The role of L-DOPA
27. Evaluation of vascular risk factors in patients with Parkinson's syndrome
28. Stroke and Parkinson's disease